Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
Protara Therapeutics, Inc. (TARA)
Company Research
Source: GlobeNewswire
On track to report interim data in six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in 4Q 2024Expect to report interim 12-month data in ADVANCED-2 trial of TARA-002 in NMIBC in mid-2025In pediatric LMs patients, TARA-002 demonstrated encouraging results and was generally well-tolerated in the first cohort of Phase 2 STARBORN-1 trial; initial results from next cohort expected in 1H 2025Received Fast Track designation from the U.S. FDA for IV Choline Chloride; expect to dose first patient in THRIVE-3 registrational trial in 1Q 2025 NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today provided a business update and announced financial results for the third quarter ended September 30, 2024. “We continue to make significant progress advancing all of our ongoing programs as we strive toward our goal of bringing life-chan
Show less
Read more
Impact Snapshot
Event Time:
TARA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TARA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TARA alerts
High impacting Protara Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TARA
News
- Protara Therapeutics, Inc. (NASDAQ: TARA) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $22.00 price target on the stock.MarketBeat
- Protara Therapeutics, Inc. (NASDAQ: TARA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.MarketBeat
- Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update [Yahoo! Finance]Yahoo! Finance
- Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business UpdateGlobeNewswire
- Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care ConferenceGlobeNewswire
TARA
Earnings
- 11/12/24 - In-Line
TARA
Analyst Actions
- 3/6/25 - HC Wainwright
TARA
Sec Filings
- 3/7/25 - Form SCHEDULE
- 3/5/25 - Form S-8
- 3/5/25 - Form 10-K
- TARA's page on the SEC website